Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Effective ways to prevent arthropathy in severe hemophilia are unknown. METHODS: We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses totaling a minimum of 80 IU of factor VIII per kilogram of body weight at the time of a joint hemorrhage. The primary outcome was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, and elbows) by radiography or magnetic resonance imaging (MRI). RESULTS: Sixty-five boys younger than 30 months of age were randomly assigned to prophylaxis (32 boys) or enhanced episodic therapy (33 boys). When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group were considered to have normal index-joint structure on MRI (P=0.006). The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% confidence interval, 1.5 to 24.4). The mean annual numbers of joint and total hemorrhages were higher at study exit in the episodic-therapy group than in the prophylaxis group (P<0.001 for both comparisons). High titers of inhibitors of factor VIII developed in two boys who received prophylaxis; three boys in the episodic-therapy group had a life-threatening hemorrhage. Hospitalizations and infections associated with central-catheter placement did not differ significantly between the two groups. CONCLUSIONS: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although effective, ERT is limited by an approximately 40% noncompliance rate, costs ≥$200,000 annually, and advances arthropathy.172, 173, 174, 175”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [172]
Citations
Cites
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
NILSSON, I. M., BERNTORP, E., LÖFQVIST, T., & PETTERSSON, H. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00546.x · Cited by 961
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
ALEDORT, L. M., HASCHMEYER, R. H., PETTERSSON, H., & THE ORTHOPAEDIC OUTCOME STUDY GROUP (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00815.x · Cited by 611
A Radiologic Classification of Hemophilic Arthropathy
PETTERSSON, H., AHLBERG, Å., & NILSSON, I. M. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198006000-00018 · Cited by 549
Proceedings: A more uniform measurement of factor VIII inhibitors.
Ck, K., Aledort, L. M., Aronson, D. D., Counts, R., Edson, van Eys, J., Fratantoni, J. C., Green, D., Hampton, J., Hilgartner, M. W., et al. (1975) · PubMed · Cited by 346
Barriers to compliance with prophylaxis therapy in haemophilia
Hacker, M. R., Geraghty, S., & Manco-Johnson, M. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00534.x · Cited by 261
Self-citationAhlberg, Å. (1965) · Acta Orthopaedica Scandinavica · doi:10.3109/ort.1965.36.suppl-77.01 · Cited by 252
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
Soucie, J. M. (2004) · Blood · doi:10.1182/blood-2003-05-1457 · Cited by 244
Self-citationIorio, A., Marchesini, E., Marcucci, M., Stobart, K., & Chan, A. K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003429.pub4 · Cited by 192
Nuss, R., Kilcoyne, R. F., Geraghty, S., Shroyer, A. L. W., Rosky, J. W., Mawhinney, S., Wiedel, J., & Manco‐Johnson, M. (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00383.x · Cited by 159
Self-citationLee, C. A., Kessler, C. M., Varon, D., Martinowitz, U. P., Heim, M., Kreuz, W., Escuriola‐Ettingshausen, C., Funk, M. J., SCHMIDT, H., & Kornhuber, B. (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.440413.x · Cited by 154
Research works printed but not linked: 5
- Robinson PM, 1967, Can Med Assoc J, 97, 559
- Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. Medical bulletin #193. New York: National Hemophilia Foundation, March 11, 1994.
- Stobart K, 2006, Cochrane Database Syst Rev, 2, CD003429
- Kasper CK, 1975, Thromb Diath Haemorr, 34, 612
- Report on the Universal Data Collection Program. Atlanta: Centers for Disease Control and Prevention, 2005;7(1):28. (Accessed July 18, 2007, athttp://www.cdc.gov/ncbddd/hbd/documents/UDC7%281%29.pdf.)
Cited by
Items 201–300 of 1,000
Hermans, C. R. J. R., de Moerloose, P., Fischer, K., Holstein, K., Klamroth, R., LAMBERT, T., Lavigne-Lissalde, G., Pérez, R. M. Á., Richards, M., Dolan, G., et al. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2010.02449.x · Cited by 68
Exploring the biological basis of haemophilic joint disease: experimental studies
Valentino, L. A., HAKOBYAN, N., Enockson, C., Simpson, M. L., KAKODKAR, N. C., CONG, L., & Song, X. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02669.x · Cited by 79
Self-citationSun, J., Hakobyan, N., Valentino, L. A., Feldman, B. L., Samulski, R. J., & Monahan, P. E. (2008) · Blood · doi:10.1182/blood-2008-01-131417 · Cited by 68
Self-citationHalf-life extension through albumin fusion technologies
Schulte, S. (2009) · Thrombosis Research · doi:10.1016/s0049-3848(09)70157-4 · Cited by 68
“Treatment with clotting factor concentrates has helped normalize life expectancy and reduce chronic joint disease [2,3].”
BackgroundEmerging clinical concerns in the ageing haemophilia patient
Konkle, B. A., Kessler, C. M., Aledort, L. M., ANDERSEN, J., Fogarty, P. F., Kouides, P. A., Quon, D. V. K., Ragni, M. V., Zakarija, A., & Ewenstein, B. M. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02066.x · Cited by 73
Melchiorre, D., Linari, S., Manetti, M., Romano, E., Sofi, F., Matucci‐Cerinic, M., Carulli, C., Innocenti, M., Ibba‐Manneschi, L., & Castaman, G. (2015) · Haematologica · doi:10.3324/haematol.2015.133462 · Cited by 75
Pierce, G. F., Adediran, M., Diop, S., Dunn, A. L., Ekiaby, M. E., Kaczmarek, R., Konkle, B. A., Pipe, S. W., Skinner, M. W., Valentino, L. A., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00209-5 · Cited by 88
Self-citationHaemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment
Roosendaal, G., Jansen, N. W. D., Schutgens, R. E. G., & Lafeber, F. P. J. G. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01882.x · Cited by 67
Acharya, S. S. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08919.x · Cited by 67
Sabatino, D. E., Nichols, T. C., Merricks, E., Bellinger, D. A., Herzog, R. W., & Monahan, P. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-394596-9.00006-8 · Cited by 66
“Clinically, this correlates with findings that hemophilia A pediatric patients that receive regular recombinant FVIII (rFVIII) treatments are 83% less likely to develop bone and cartilage changes compared to episodic treatments for bleeding.(42) Using these mouse models to measure the impact of bleeding on the joint i…”
BackgroundCollins, P. W., MØSS, J., Knobe, K. E., GROTH, A., Colberg, T., & WATSON, E. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12000 · Cited by 66
Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens
Berntorp, E. E. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02077.x · Cited by 66
Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A
Kepa, S., Horvath, B., Reitter-Pfoertner, S., SCHEMPER, M., Quehenberger, P., Grundbichler, M., Heistinger, M., Neumeister, P., Mannhalter, C., & Pabinger, I. (2015) · Haemophilia · doi:10.1111/hae.12592 · Cited by 66
Individualizing prophylaxis in hemophilia: a review
Petrini, P., Valentino, L. A., Gringeri, A., Re, W. M., & Ewenstein, B. M. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1002465 · Cited by 65
“Analysis of another cohort of patients with severe hemophilia A demonstrated that some patients with no clinically evident joint bleeding had MRI evidence of damage, whereas others with multiple bleeding episodes had normal MRI findings [2].”
BackgroundSelf-citationTreatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
Rocino, A., Franchini, M., & Coppola, A. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6040046 · Cited by 65
“The role of unrecognised, subclinical joint bleeds was hypothesised in the US Joint Outcome Study, in which 65 children <30 months old with severe haemophilia A were randomised to FVIII prophylaxis or enhanced episodic therapy, and followed up for five years [85].”
Chowdary, P. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2548-6 · Cited by 69
van Os, S., Troop, N., Sullivan, K. R., & Hart, D. P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169880 · Cited by 65
Mackensen, S. V., Kalnins, W., Joerg, K., Weiss, J., Miesbach, W., Albisetti, M., Pabinger, I., & Oldenburg, J. (2017) · Haemophilia · doi:10.1111/hae.13221 · Cited by 65
The EANM guideline for radiosynoviorthesis
Kampen, W. U., Boddenberg-Pätzold, B., Fischer, M., Gabriel, M., Klett, R., Konijnenberg, M., Kresnik, E., Lellouche, H., Paycha, F., Terslev, L., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05541-7 · Cited by 64
Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A
García‐Dasí, M., Aznar, J. A., Jiménez‐Yuste, V., Altisent, C., Bonanad, S., Mingot‐Castellano, M. E., Lucía, F., Giménez, F., Fernández, M. F. L., Marco, P., et al. (2015) · Haemophilia · doi:10.1111/hae.12618 · Cited by 64
Haemophilia B: impact on patients and economic burden of disease
Thomson, T., Strandberg-Larsen, M., & Gater, A. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-03-0193 · Cited by 64
“For example, primary prophylaxis (introduced before joint haemorrhages have occurred), may prevent joint damage and decrease the likelihood of arthropathy and other long-term morbidities (54, 56, 60).”
Valentino, L. A., Pipe, S. W., Collins, P., Blanchette, V. S., Berntorp, E. E., Fischer, K., Ewenstein, B. M., Oh, M., & Spotts, G. E. (2016) · Haemophilia · doi:10.1111/hae.12905 · Cited by 64
Self-citationMercan, A., Sarper, N., Inanir, M., Mercan, H. İ., Zengin, E., Kılıç, S. Ç., & Gökalp, A. S. (2010) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2010.489933 · Cited by 63
“Manco-Jonson et al’s study [13] in randomly assigned young boys for prophylaxis (32 boys) or enhanced episodic therapy (33 boys) showed that prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in severe hemophilia A.”
BackgroundNovel therapies and current clinical progress in hemophilia A
Balkaransingh, P., & Young, G. A. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717746312 · Cited by 68
The benefits of prophylaxis in patients with hemophilia B
Castaman, G. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1489719 · Cited by 64
“no clinically evident bleeds, suggesting that subclinical bleeds occur due to apparent under-treatment [4,86].”
BackgroundGouw, S. C., Timmer, M. A., Srivastava, A., de Kleijn, P., Hilliard, P., Peters, M., Blanchette, V. S., & Fischer, K. (2018) · Haemophilia · doi:10.1111/hae.13631 · Cited by 63
Holm, E., Abshire, T. C., Bowen, J. M., Alvárez, M. T., Bolton‐Maggs, P. H. B., Carcao, M. D., Federici, A. B., Gill, J. C., Halimeh, S., Kempton, C. L., et al. (2015) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000257 · Cited by 62
Self-citationKlamroth, R., Pöllmann, H., Hermans, C. R. J. R., Faradji, A., Yarlas, A. S., Epstein, J., & Ewenstein, B. M. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2010.02435.x · Cited by 62
Poonnoose, P. M., Hilliard, P., Doria, A. S., Keshava, S. N., Gibikote, S., KAVITHA, M. L., Feldman, B. M., Blanchette, V. S., & Srivastava, A. (2016) · Haemophilia · doi:10.1111/hae.13023 · Cited by 62
Costs of Care in Hemophilia and Possible Implications of Health Care Reform
Johnson, K. A., & Zhou, Z. (2011) · Hematology · doi:10.1182/asheducation-2011.1.413 · Cited by 74
The current status of prophylactic replacement therapy in children and adults with haemophilia
Ljung, R. C. R., & Andersson, N. G. (2015) · British Journal of Haematology · doi:10.1111/bjh.13365 · Cited by 60
Kulkarni, R., Karim, F. A., Glamocanin, S., Janić, D., Vdovin, V., Ozelo, M. C., Ragelienė, L., Carboni, E. K., Laguna, P. J., Dobaczewski, G., et al. (2013) · Haemophilia · doi:10.1111/hae.12165 · Cited by 61
Fischer, K., Collins, P. W., Ozelo, M. C., Srivastava, A., Young, G. A., & Blanchette, V. S. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13298 · Cited by 61
Meunier, S., Alamelu, J., Ehrenforth, S., Hanabusa, H., Karim, F. A., Kavaklı, K., Khodaie, M., Staber, J. M. R., Stasyshyn, O., Yee, D. L., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0166 · Cited by 60
“While FVIII therapy can be provided prophylactically or on-demand, prophylaxis is preferred for children because it reduces bleeding frequency, prevents long-term structural joint damage and preserves musculo skeletal function (1, 2).”
BackgroundEmicizumab: Review of the literature and critical appraisal
Rodriguez-Merchan, E. C., & Valentino, L. A. (2018) · Haemophilia · doi:10.1111/hae.13641 · Cited by 60
“(7) Bleeding episodes should not be managed with aPCC unless no other alternative is available.”
BackgroundSelf-citationGringeri, A., Leissinger, C., Cortesi, P. A., Jo, H., Fusco, F., Riva, S., Antmen, B., Berntorp, E. E., Biasoli, C., Carpenter, S., et al. (2013) · Haemophilia · doi:10.1111/hae.12178 · Cited by 60
Self-citationOldenburg, J., Zimmermann, R., Κατσαρού, Ό., Theodossiades, G., Zanon, E., Niemann, B., Kellermann, E., Lundin, B., & the Cross‐sectional MRI study investigators (2014) · Haemophilia · doi:10.1111/hae.12539 · Cited by 60
Current and emerging factor VIII replacement products for hemophilia A
Cafuir, L. A., & Kempton, C. L. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717721458 · Cited by 69
Recent advances in musculoskeletal physiotherapy for haemophilia
Stephensen, D., Bladen, M., & McLaughlin, P. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718784834 · Cited by 60
Lugin, M. L., Lee, R. T., & Kwon, Y. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c03850 · Cited by 63
Role of enhanced half‐life factor VIII and IX in the treatment of haemophilia
Mahdi, A. J., Obaji, S. G., & Collins, P. W. (2015) · British Journal of Haematology · doi:10.1111/bjh.13360 · Cited by 61
Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status
Curtis, R., Baker, J., Riske, B., Ullman, M. M., Niu, X., Norton, K. L., Lou, M., & Nichol, M. B. (2015) · American Journal of Hematology · doi:10.1002/ajh.24218 · Cited by 59
“However, the first randomized clinical trial of prophylaxis benefits in the world was not published until 2007 [38].”
BackgroundSelf-citationJiménez‐Yuste, V., Auerswald, G., Benson, G. M., Lambert, T., Morfini, M., Remor, E., & Šalek, S. Z. (2014) · PubMed · doi:10.2450/2014.0298-13 · Cited by 61
Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
Samelson-Jones, B. J., & Arruda, V. R. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.007 · Cited by 58
The role of physical medicine and rehabilitation in haemophiliac patients
la Corte‐Rodríguez, H. D., & Rodriguez-Merchan, E. C. (2012) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32835a72f3 · Cited by 58
Management of joint bleeding in hemophilia
Simpson, M. L., & Valentino, L. A. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.27 · Cited by 58
Self-citationMcEneny‐King, A., Iorio, A., Foster, G., & Edginton, A. N. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1214711 · Cited by 61
Haxaire, C., Hakobyan, N., Pannellini, T., Carballo, C. B., McIlwain, D. R., Mak, T. W., Rodeo, S. A., Acharya, S., Li, D., Szymonifka, J. D., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820571 · Cited by 62
Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A
Cook, K., Forbes, S. P., Adamski, K. N., Janice, J., Chawla, A., & Garrison, L. P. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1721508 · Cited by 60
Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A
Malec, L. M., Peyvandi, F., Chan, A. K. C., Königs, C., Zülfikar, B., Yuan, H., Simpson, M. L., Román, M. T. Á., Carcao, M. D., Staber, J. M. R., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312611 · Cited by 62
Gorczyca, M. E., Nair, S. C., Jilma, B., Priya, S., Male, C., Reitter, S. E., Knöbl, P., Gilbert, J. C., Schaub, R. G., Dockal, M., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04790.x · Cited by 57
Improvements in factor concentrates
Lillicrap, D. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32833c06c6 · Cited by 57
Quality of life in adult patients with haemophilia – a single centre experience from Sweden
Lindvall, K., Mackensen, S. V., & Berntorp, E. E. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02765.x · Cited by 59
Zappa, S. C., McDaniel, M., Marandola, J., & Allen, G. A. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02770.x · Cited by 57
Towards comprehensive care in transition for young people with haemophilia
Breakey, V. R., Blanchette, V. S., & Bolton‐Maggs, P. H. B. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02249.x · Cited by 58
Hemophilia trials in the twenty‐first century: Defining patient important outcomes
Konkle, B. A., Skinner, M. W., & Iorio, A. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12195 · Cited by 63
Impact of novel hemophilia therapies around the world
Ozelo, M. C., & Yamaguti-Hayakawa, G. G. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12695 · Cited by 63
Mahlangu, J. N., Lamas, J. L., Morales, J. C., Malan, D. R., Šalek, S. Z., Wang, M., Boggio, L. N., Hegemann, I., Mital, A., Cardinal, M., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18420 · Cited by 64
The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A
Soucie, J. M., WANG, C., Siddiqi, A., Kulkarni, R., Recht, M., & Konkle, B. A. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2010.02400.x · Cited by 63
Self-citationJiménez‐Yuste, V., ALVAREZ, M. T., Martín‐Salces, M., QUINTANA, M., Rodríguez-Merchán, C. E., Lopez‐Cabarcos, C., Velasco, F., & Hernandez-Navarro, F. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01915.x · Cited by 56
“Prophylaxis with the deficient factor can prevent joint damage and decrease the frequency of haemarthrosis and life-threatening haemorrhages [ 1 ].”
Herzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
The Universal Data Collection Surveillance System for Rare Bleeding Disorders
Soucie, J. M., McAlister, S., McClellan, A. C., Oakley, M. A., & Su, Y. (2010) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2009.12.023 · Cited by 58
Self-citationFischer, K., Collins, P. W., Björkman, S. E., Blanchette, V. S., Oh, M., Fritsch, S. R. S., Schroth, P., Spotts, G. E., & Ewenstein, B. M. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2010.02450.x · Cited by 55
Haemophilia Care in Europe: the ESCHQoL study
Schramm, W., Gringeri, A., Ljung, R. C. R., Berger, K., Crispin, A., Bullinger, M., Giangrande, P. L. F., Mackensen, S. V., Mantovani, L. G., Nemes, L., et al. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02847.x · Cited by 55
van Galen, K. P. M., Sanders, Y. V., Vojinovic, U., Eikenboom, J. C. J., Cnossen, M. H., Schutgens, R. E. G., van der Bom, J. G., Fijnvandraat, K., Gorkom, B. A. P. L., Meijer, K., et al. (2015) · Haemophilia · doi:10.1111/hae.12670 · Cited by 55
Advances in gene therapy for hemophilia: basis, current status, and future perspectives
Ohmori, T. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2513-4 · Cited by 92
Rare Bleeding Disorders in Children: Identification and Primary Care Management
Acharya, S. S. (2013) · PEDIATRICS · doi:10.1542/peds.2012-3662 · Cited by 54
Prophylactic therapy in haemophilia
Ljung, R. C. R. (2009) · Blood Reviews · doi:10.1016/j.blre.2009.08.001 · Cited by 54
Kavaklı, K., Smith, L., Kuliczkowski, K., Korth-Bradley, J. M., You, C. W., Fuiman, J., Zupančić‐Šalek, S., Karim, F. A., & Rendo, P. (2016) · Haemophilia · doi:10.1111/hae.12878 · Cited by 54
Saxena, K., Lalezari, S., Oldenburg, J., Tseneklidou‐Stoeter, D., Beckmann, H., Yoon, M., & Enriquez, M. M. (2016) · Haemophilia · doi:10.1111/hae.12952 · Cited by 56
Lissitchkov, T. J., Rusen, L., Georgiev, P., Windyga, J., Klamroth, R., Gercheva, L., Nemes, L., Tiede, A., Bichler, J., Knaub, S., et al. (2017) · Haemophilia · doi:10.1111/hae.13251 · Cited by 54
Skinner, M. W., Chai‐Adisaksopha, C., Curtis, R., Frick, N., Nichol, M. B., Noone, D., O’Mahony, B., Page, D., Stonebraker, J. S., & Iorio, A. (2018) · Pilot and Feasibility Studies · doi:10.1186/s40814-018-0253-0 · Cited by 54
“Prophylaxis has been shown capable of maintaining joint status and function [6], but adequate prophylaxis requires lifetime self-administration of factor concentrate two to three times per week.”
BackgroundCarcao, M. D., Zak, M., Karim, F. A., Hanabusa, H., Kearney, S. L., Lu, M., Persson, P., Rangarajan, S., & Santagostino, E. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13360 · Cited by 53
The role of orthopaedic surgery in haemophilia: current rationale, indications and results
Rodriguez-Merchan, E. C. (2019) · EFORT Open Reviews · doi:10.1302/2058-5241.4.180090 · Cited by 53
Fletcher, S. J., Jenner, K., Pembroke, L., Holland, M., & Khair, K. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02256-2 · Cited by 57
“Background Haemophilia affects 1:3333 men worldwide [1], resulting in recurrent joint and muscle bleeding leading to joint arthropathy, muscle contracture and significant disability [2, 3].”
BackgroundProphylactic Treatment for Prevention of Joint Disease in Hemophilia — Cost versus Benefit
Roosendaal, G., & Lafeber, F. P. J. G. (2007) · New England Journal of Medicine · doi:10.1056/nejme078098 · Cited by 53
Astermark, J., Santagostino, E., & Hoots, W. K. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02294.x · Cited by 52
Self-citationFoppen, W., van der Schaaf, I. C., & Fischer, K. (2015) · Haemophilia · doi:10.1111/hae.12769 · Cited by 52
Earnshaw, S., Graham, C. N., McDade, C. L., Spears, J. B., & Kessler, C. M. (2015) · Haemophilia · doi:10.1111/hae.12621 · Cited by 54
Recht, M., Liel, M. S., Turner, R. T., Klein, R. F., & Taylor, J. A. (2013) · Haemophilia · doi:10.1111/hae.12195 · Cited by 52
Self-citationSantagostino, E., Lentz, S. R., Busk, A. K., Regnault, A., & Iorio, A. (2014) · Haemophilia · doi:10.1111/hae.12371 · Cited by 52
Narkbunnam, N., Sun, J., Hu, G., Lin, F.-C., Bateman, T. A., Mihara, M., & Monahan, P. E. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12176 · Cited by 57
“This distinction between these subsets of patients was recently underscored by the prospectively generated results of the Joint Outcome Study, in which some boys who reported multiple joint bleeding episodes remained free of MRI evidence of disease, while others with minimal or no reported hemarthroses nevertheless ma…”
ResultSetting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?
Hazendonk, H. C. A. M., van Moort, I., Mathôt, R. A. A., Fijnvandraat, K., Leebeek, F. W. G., Collins, P. W., & Cnossen, M. H. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.01.001 · Cited by 56
“Consequently, hemophilia has evolved from a crippling disease with a shortened life expectancy into a disease with a normal life expectancy, significantly less joint arthropathy and acceptable quality of life [11,12].”
BackgroundTeranishi-Ikawa, Y., Soeda, T., Koga, H., Yamaguchi, K., Kato, K., Esaki, K., Asanuma, K., Funaki, M., Ichiki, M., Ikuta, Y., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.09.034 · Cited by 57
Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors
Valentino, L. A. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02126.x · Cited by 54
Self-citationMartinowitz, U. P., Bjerre, J., Brand, B., Klamroth, R., Misgav, M., Morfini, M., Santagostino, E., Tiede, A., & Viuff, D. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02495.x · Cited by 51
Managing chronic pain in adults with haemophilia: current status and call to action
Humphries, T. J., & Kessler, C. M. (2014) · Haemophilia · doi:10.1111/hae.12526 · Cited by 53
Auerswald, G., Bidlingmaier, C., & Kurnik, K. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02659.x · Cited by 51
Musculo-skeletal manifestations of haemophilia
Rodriguez-Merchan, E. C. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.04.008 · Cited by 51
“With adequate prophylaxis, at least from the age of 2 to 18 (ideally lifelong), it is possible to convert severe haemophilia into a moderate condition, considerably reducing (although not totally preventing) the associated musculo-skeletal problems [5–7].”
BackgroundDifferential effects of bleeds on the development of arthropathy – basic and applied issues
van Vulpen, L. F. D., Mastbergen, S. C., Lafeber, F. P. J. G., & Schutgens, R. E. G. (2017) · Haemophilia · doi:10.1111/hae.13236 · Cited by 51
2021 clinical trials update: Innovations in hemophilia therapy
Croteau, S. E., Wang, M., & Wheeler, A. P. (2020) · American Journal of Hematology · doi:10.1002/ajh.26018 · Cited by 54
“Pediatric patients present both a unique challenge and an opportunity as prevention of joint bleeding, particularly at the youngest ages, greatly improves overall joint health.(1,120) Development of therapeutic strategies that are easily administered and provide robust hemostatic protection are appealing.”
BackgroundCurrent and future therapies for haemophilia—Beyond factor replacement therapies
Nogami, K., & Shima, M. (2022) · British Journal of Haematology · doi:10.1111/bjh.18379 · Cited by 52
“Advances in regular prophylactic treatment using clotting factor concentrates were found to sufficiently control haemarthrosis and suppress the onset of arthropathy, contributing to marked improvements in the patient's quality of life.(3) However, more effective and less burdensome therapeutics designed to overcome so…”
BackgroundWALSH, C. E., & Valentino, L. A. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02036.x · Cited by 50
Self-citationBiological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
Turecek, P. L., Johnsen, J. M., Pipe, S. W., O’Donnell, J. S., & the iPATH study group (2020) · Haemophilia · doi:10.1111/hae.14078 · Cited by 61
Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes
Altisent, C., Martorell, M., Crespo-Fresno, A., Casas, L., Torrents, C., & Parra, R. (2015) · Haemophilia · doi:10.1111/hae.12792 · Cited by 49
Lindvall, K., Astermark, J., Björkman, S. E., Ljung, R. C. R., Carlsson, K. S., Persson, S., & Berntorp, E. E. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02879.x · Cited by 49
Monahan, P. E., Liesner, R. J., SULLIVAN, S. T., Ramirez, M. E., KELLY, P., & Roth, D. A. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2009.02162.x · Cited by 49
Ettingshausen, C. E., & Kreuz, W. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02116.x · Cited by 49
Pasca, S., Milan, M., Sarolo, L., & Zanon, E. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.07.003 · Cited by 49
Hilliard, P., Zourikian, N., Blanchette, V. S., Chan, A. K. C., Elliott, B., Israels, S. J., Nilson, J., Poon, M., Laferriere, N., Neste, C. V., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12113 · Cited by 48
Metadata
- Authors
- Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G. A., Thompson, A. A., McRedmond, K., Soucie, J. M., Austin, H., & Evatt, B. L.
- Affiliations
- University of Colorado Denver (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-08-09
- Volume
- 357
- Issue
- 6
- Pages
- 535-544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167801052
- Cited by
- 1,950
- References
- 27
- Citations by year
- 2026: 57 · 2025: 70 · 2024: 98 · 2023: 115 · 2022: 106 · 2021: 123 · 2020: 127 · 2019: 110 · 2018: 114 · 2017: 107 · 2016: 123 · 2015: 116 · 2014: 131 · 2013: 116 · 2012: 112
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (U27/CCU812106, R00069)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hemophilia A, severe hemophilia, prophylaxis, episodic treatment, recombinant factor VIII, joint destruction, factor VIII inhibitors, joint hemorrhage, children, central venous catheter complications
- MeSH terms
- Child, Child, Preschool, Drug Administration Schedule, Factor VIII, Follow-Up Studies, Hemarthrosis, Hemophilia A, Hemorrhage, Humans, Infant, Infusions, Intravenous, Joint Diseases, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.